| Candidates | Preclinical | Phase 1 | Phase 2 | Phase 3 | reg. filing | marketed | |
|---|---|---|---|---|---|---|---|
| Tivozanib (RCC) VEGFR TKI |
TIVO - 3 | ||||||
| TIVO - 1 | |||||||
| TiNivo - 2 | |||||||
| Tivozanib (HCC) VEGFR TKI |
DEDUCTIVE | ||||||
| Ficlatuzumab Anti-HGF/c-MET IgG1 mAb |
HNSCC | ||||||
| Pancreatic | |||||||
| AML | |||||||
| AV-380 Anti-GDF15 IgG1 mAb |
Cachexia | ||||||
| AV-203 Anti-ERBB3 mAb |
Oncology | ||||||
| AV-353 Anti-Notch 3 mAb |
Oncology | ||||||
| Tivozanib (RCC) VEGFR TKI |
||
| TIVO - 3 | marketed | |
| TIVO - 1 | marketed | |
| TiNivo - 2 | Phase 3 | |
| Tivozanib (HCC) VEGFR TKI |
||
| DEDUCTIVE | Phase 2 | |
| Ficlatuzumab Anti-HGF/c-MET IgG1 mAb |
||
| HNSCC | Phase 2 | |
| Pancreatic | Phase 2 | |
| AML | Phase 2 | |
| AV-380 Anti-GDF15 IgG1 mAb |
||
| Cachexia | Phase 1 | |
| AV-203 Anti-ERBB3 mAb |
||
| Oncology | Phase 1 | |
| AV-353 Anti-Notch 3 mAb |
||
| Oncology | Preclinical | |
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO’s strategy is to focus its resources toward development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO’s lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval in March 2021for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck squamous cell carcinoma (HNSCC), pancreatic cancer and acute myeloid leukemia, and expects to make a go/no-go decision on the initiation of a pivotal Phase 3 study of ficlatuzumab in HPV negative HNSCC following feedback from the FDA. AVEO’s pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO’s earlier stage pipeline includes several monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb), and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.
FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.1,2
For more information, please visit FOTIVDA
Ficlatuzumab, AV-203, AV-380 and AV-353 are investigational drugs and have not yet been approved by the U.S. Food and Drug Administration (FDA).
1Fotivda (Tivozanib) SmPC August 2017
2Motzer RJ, Nosov D, Eisen T, et al. J Clin Oncol 2013; 31(30): 3791-9
